Stem cells-derived in vitro meat: from petri dish to dinner plate

Author(s):  
Anshuman Singh ◽  
Vinod Verma ◽  
Manoj Kumar ◽  
Ashok Kumar ◽  
Devojit Kumar Sarma ◽  
...  
Keyword(s):  
2006 ◽  
Vol 68 (1) ◽  
Author(s):  
Larry J. Pittman

Many Americans die each day from diseases affecting the heart, liver, kidneys, brain and a whole host of other bodily organs. Scientific researchers are constantly trying to develop new treatments for such medical conditions. Presently, the research community is working hard to develop medical treatments using stem cells from human embryos. That process involves extracting stem cells from either excess embryos that are no longer needed for in vitro fertilization or from embryos that are created through therapeutic cloning. At the blastocyst stage, about five days after the beginning of an embryo, researchers extract stem cells from the embryo and place them in a petri dish where the cells divide to produce a line of millions of stem cells. These stem cells are undifferentiated, meaning that they are still capable of transforming themselves into many different types of cells that exist in the human body. The hope is that physicians and other medical personnel will one day be able to inject these stem cells into a patient’s diseased heart, kidney, brain, liver, spinal cord or other organ, and the stem cells willtransform themselves into the same type of cells that comprise the host organ. The expectation is that the stem cells will repair the patient’s heart or other organs by curing diseases and otherwise improving the patient’s medical condition and life expectancy.


Author(s):  
Jonathon Keats

According to the eminent seventeenth-century botanist John Parkinson, one of the plants that grew in the Garden of Eden was the vegetable lamb. Also known as the borametz, this creature resembled a young sheep in every important respect, except that it grew from a seed planted in the ground. Reports of it date back at least as far as Herodotus, and the fourteenth-century explorer John Mandeville claimed, in his notoriously unreliable Voyages and Travel , to have tasted one “although it were wonderful.” Only in the 1800s was the legend debunked, largely on the initiative of the British naturalist Henry Lee. (He convincingly speculated that borametz rumors began with the spread of the cotton plant, which to an untutored eye looked as woolly as a sheep.) Yet the dream of cultivating meat off the hoof, of growing muscle without the animal, was not so easily dismissed. In his 1931 book, Fifty Years Hence , no less a figure than Winston Churchill anticipated a time when “we shall escape the absurdity of growing a whole chicken in order to eat the breast or wing, by growing these parts separately under a suitable medium.” He didn’t live to see it happen. Half a century passed and vegetable meat remained as elusive as the Garden of Eden. But the technologies necessary for cultivation were evolving, quietly developing as researchers studied subjects as far afield as organ transplants and stem cells. Gradually a few laboratories, some of them funded to develop tastier astronaut cuisine for NASA, began growing potentially edible animal tissues in a bioreactor. Then everything changed again in 2008, when People for the Ethical Treatment of Animals (PETA) announced a prize of $1 million to the first person to produce “an in vitro chicken-meat product that has a taste and texture indistinguishable from real chicken flesh to non-meat-eaters and meat-eaters alike.” Almost overnight in vitro meat, or at least the idea of it, was headline news: The ancient dream, newly named, went prime time.


2019 ◽  
Vol 3 (6) ◽  
pp. 753-758
Author(s):  
Silvia Woll

Innovators of in vitro meat (IVM) are convinced that this approach is the solution for problems related to current meat production and consumption, especially regarding animal welfare and environmental issues. However, the production conditions have yet to be fully clarified and there is still a lack of ethical discourses and critical debates on IVM. In consequence, discussion about the ethical justifiability and desirability of IVM remains hypothetical and we have to question those promises. This paper addresses the complex ethical aspects associated with IVM and the questions of whether, and under what conditions, the production of IVM represents an ethically justifiable solution for existing problems, especially in view of animal welfare, the environment, and society. There are particular hopes regarding the benefits that IVM could bring to animal welfare and the environment, but there are also strong doubts about their ethical benefits.


2019 ◽  
Vol 98 (9) ◽  
pp. 350-355

Introduction: There is evidence that mesenchymal stem cells (MSCs) could trans-differentiate into the liver cells in vitro and in vivo and thus may be used as an unfailing source for stem cell therapy of liver disease. Combination of MSCs (with or without their differentiation in vitro) and minimally invasive procedures as laparoscopy or Natural Orifice Transluminal Endoscopic Surgery (NOTES) represents a chance for many patients waiting for liver transplantation in vain. Methods: Over 30 millions of autologous MSCs at passage 3 were transplanted via the portal vein in an eight months old miniature pig. The deposition of transplanted cells in liver parenchyma was evaluated histologically and the trans-differential potential of CM-DiI labeled cells was assessed by expression of pig albumin using immunofluorescence. Results: Three weeks after transplantation we detected the labeled cells (solitary, small clusters) in all 10 samples (2 samples from each lobe) but no diffuse distribution in the samples. The localization of CM-DiI+ cells was predominantly observed around the portal triads. We also detected the localization of albumin signal in CM-DiI labeled cells. Conclusion: The study results showed that the autologous MSCs (without additional hepatic differentiation in vitro) transplantation through the portal vein led to successful infiltration of intact miniature pig liver parenchyma with detectable in vivo trans-differentiation. NOTES as well as other newly developed surgical approaches in combination with cell therapy seem to be very promising for the treatment of hepatic diseases in near future.


2013 ◽  
Author(s):  
Melo Ocarino Natalia de ◽  
Silvia Silva Santos ◽  
Lorena Rocha ◽  
Juneo Freitas ◽  
Reis Amanda Maria Sena ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document